• An international, multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes.
    • Cheeseman S, Levick B, Sopwith W, Fenton H, Nam EJ, Kim DK, Lim S, Martin E, FRENEL JS, Bocquet F, Kubelac P, Achimas-Cadariu P, Vlad C, Chevrier M, Rouzier R, Carton M, Savva-Bordalo J, Magalhães M, Borges M, Wolf A, Becker S, Niklas N, Guergova-Kuras M, Hall G.
    • Front Oncol. 2023 Jan 9;12:1114435. doi: 10.3389/fonc.2023.1114435.
    • Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS.
    • Acs M, Gerken M, Schmitt V, Piso P, Alfred Königsrainer A, Baransi S, Yurttas C, Häusler S, Horvath P.
    • Cancers (Basel). 2023 Jan 7;15(2):405. doi: 10.3390/cancers15020405.
    • Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report.
    • Bian Y, Guan P, Li D, Tan L, Pang H, Wen Q, Chen P, Zhang Z.
    • Front Oncol. 2022 Dec 15;12:1071383. doi: 10.3389/fonc.2022.1071383.
    • Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer.
    • Li C, Ye W, Zhou W, Ye Z, Yang W, Cheng Z.
    • Front Oncol. 2022 Dec 12;12:1010158. doi: 10.3389/fonc.2022.1010158.
    • Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
    • Bhatt A, Bhandoria G, Kepenekian V, Bakrin N, Glehen O.
    • Int J Cancer. 2022 Dec 1;151(11):2055-2056. doi: 10.1002/ijc.34220. Epub 2022 Aug 5.
    • Comment. Letter.

    Related:

    Reply, Letter:

    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    Original research:

    Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.

    • Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations.
    • Sanders BE, Wolsky R, Doughty ES, Wells KL, Ghosh D, Ku L, Pressey JG, Bitler BB, Brubaker LW.
    • Gynecol Oncol Rep. 2022 Oct 6 [eCollection 2022 Dec];44:101077. doi: 10.1016/j.gore.2022.101077.
    • Comparing Characteristics of Pelvic High-grade Serous Carcinomas with and without Breast Cancer Gene Variants on MR Imaging.
    • Saida T, Shikama A, Mori K, Ishiguro T, Minaguchi T, Satoh T, Nakajima T.
    • Magn Reson Med Sci. 2022 Nov 12. doi: 10.2463/mrms.mp.2022-0061. Epub ahead of print.
    • PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer.
    • Doherty K, Miller EM.
    • OncLive. 2022 Nov 10.
    • Using a machine learning algorithm to predict outcome of primary cytoreductive surgery in advanced ovarian cancer.
    • Piedimonte S, Erdman L, So D, Bernardini MQ, Ferguson SE, Laframboise S, Bouchard Fortier G, Cybulska P, May T, Hogen L.
    • J Surg Oncol. 2022 Nov 9. doi: 10.1002/jso.27137. Epub ahead of print.
    • Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
    • De Jong D, Otify M, Chen I, Jackson D, Jayasinghe K, Nugent D, Thangavelu A, Theophilou G, Laios A.
    • Medicina (Kaunas). 2022 Nov 8;58(11):1611. doi: 10.3390/medicina58111611.
    • ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    • Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI.
    • Ann Surg Oncol. 2022 Nov 5. doi: 10.1245/s10434-022-12681-z. Epub ahead of print.
    • Review

    Related:

    •• Original research:

    Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

    • [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
    • Tanaka Y, Oota R, Takagi Y, Kodama W, Nishimura K, Hamasaki T, Fukino S, Suo K.
    • Gan To Kagaku Ryoho. 2022 Nov;49(11):1271-1273. Japanese.
    • Case report. [Article in Japanese]
    • Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
    • Koole SN, Schouten PC, Hauke J, Kluin RJC, Nederlof P, Richters LK, Krebsbach G, Sikorska K, Alkemade M, Opdam M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, Mom CH, Arts HJG, van Ham M, van Dam P, Vuylsteke P, Sanders J, Horlings HM, van de Vijver KK, Hahnen E, van Driel WJ, Schmutzler R, Sonke GS, Linn SC.
    • Int J Cancer. 2022 Oct 15;151(8):1394-1404. doi: 10.1002/ijc.34124. Epub 2022 Jun 4.

    Related:

    Comment, Letter:

    Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    Reply, Letter:

    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    • Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
    • Kadan Y, Kotait M, Beiner M, Hirte H, Josephy D, Salman L, Bruchim I, Pond G, Helpman L.
    • Gynecol Oncol. 2022 Sep 22:S0090-8258(22)00574-1. doi: 10.1016/j.ygyno.2022.08.020. Epub ahead of print.
    • Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    • Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI.
    • Ann Surg Oncol. 2022 Sep 9. doi: 10.1245/s10434-022-12459-3. Epub ahead of print.

    Related:

    •• Review:

    ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

    • Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer.
    • Bhatt A, Sinukumar S, Kepenekian V, Kammar P, Mehta S, Shaikh S, Gertych W, Bakrin N, Glehen O.
    • Front Oncol. 2022 Sep 2;12:951419. doi: 10.3389/fonc.2022.951419.
    • Long-term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report.
    • Bredow K, Blümcke B, Schneider S, Püsken M, Schmutzler R, Rhiem K.
    • Mol Clin Oncol. 2022 Jul 21 [eCollection 2022 Sep];17(3):137. doi: 10.3892/mco.2022.2570.
    • Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.
    • Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De La Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F.
    • Cancers (Basel). 2022 Aug 21;14(16):4040. doi: 10.3390/cancers14164040.
    • Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
    • Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Høgdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH.
    • Cancer. 2022 Aug 15;128(16):3080-3089. doi: 10.1002/cncr.34350. Epub 2022 Jun 17.
    • Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
    • Nag S, Aggarwal S, Rauthan A, Warrier N.
    • J Ovarian Res. 2022 Jul 28;15(1):88. doi: 10.1186/s13048-022-01020-1.
    • Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges.
    • Nikolaidi A, Fountzilas E, Fostira F, Psyrri A, Gogas H, Papadimitriou C.
    • Front Oncol. 2022 Jul 26;12:820128. doi: 10.3389/fonc.2022.820128.
    • The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    • Lau CH, Seow KM, Chen KH.
    • Int J Mol Sci. 2022 Jul 23;23(15):8125. doi: 10.3390/ijms23158125.
    • Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance.
    • Palluzzi E, Marchetti C, Cappuccio S, Avesani G, Macchia G, Gambacorta MA, Cocciolillo F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 Jul 22:ijgc-2022-003543. doi: 10.1136/ijgc-2022-003543. Epub ahead of print.
    • CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    • You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM.
    • J Clin Oncol. 2022 Jul 22:JCO2200430. doi: 10.1200/JCO.22.00430. Epub ahead of print.
    • Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer.
    • Cardillo N, Devor EJ, Pedra Nobre S, Newtson A, Leslie K, Bender DP, Smith BJ, Goodheart MJ, Gonzalez-Bosquet J.
    • Cancers (Basel). 2022 Jul 21;14(14):3554. doi: 10.3390/cancers14143554.
    • Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study.
    • Kim SI, Lim H, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Lee M.
    • Cancer Res Treat. 2022 Jul 19. doi: 10.4143/crt.2022.232. Epub ahead of print.
    • Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
    • You B, Van Wagensveld L, Tod M, Sonke GS, Horlings HM, Kruitwagen RFPM, Du Bois A, Selle F, Perren T, Pfisterer J, Joly F, Cook A, Kaminsky MC, Wollschlaeger K, Lortholary A, Tome O, Leary A, Freyer G, Van Der Aa M, Colomban O.
    • Br J Cancer. 2022 Jul;127(1):79-83. doi: 10.1038/s41416-022-01732-7. Epub 2022 Mar 31.
    • Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
    • Shi T, Xiang L, Zhu J, Liu J, Zhang P, Wang H, Feng Y, Zhu T, Zhang Y, Yu A, Jiang W, Wang X, Zhu Y, Wu S, Teng Y, Zhang J, Jiang R, Zhang W, Jia H, Zang R.
    • J Gynecol Oncol. 2022 Jul;33(4):e63. doi: 10.3802/jgo.2022.33.e63.

    Related:

    Original research:

    A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.

    • A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report.
    • Ngu SF, Ngan HYS, Chan KKL.
    • Cancer Drug Resist. 2022 Jun 22;5(3):662-666. doi: 10.20517/cdr.2022.12.
    • BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score.
    • Ergasti R, Marchetti C, Tudisco R, Iervolino A, Naldini A, Oliva R, Inzani F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 May 3;32(5):639-645. doi: 10.1136/ijgc-2021-003116.
    • Fallopian Tube Originating Ovarian Cancer in a 53-Year-Old Postmenopausal Female With Hereditary Breast Cancer (BRCA) Genes: A Case Study.
    • Garrick I, Ahasan H, Jiang M, Musheyev Y, Ftiha F, Levada M.
    • Cureus. 2022 Apr 7;14(4):e23929. doi: 10.7759/cureus.23929.
    • Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
    • Chalif J, Yao M, Gruner M, Kuznicki M, Vargas R, Rose PG, Michener C, DeBernardo R, Chambers L.
    • Gynecol Oncol. 2022 Apr;165(1):90-96. doi: 10.1016/j.ygyno.2022.01.026. Epub 2022 Mar 7.
    • BRCA1 Mutation: An Insidious Enemy with Multiple Facets….
    • Godin P, Duhoux FP, Mazzeo F, Rojas M, Bollue E, François A, Galant C, Coulie J, Coyette M, Lentini A, Deswisen Y, Perlepe V, Fellah L, Leconte I, Berlière M.
    • Case Rep Oncol. 2022 Mar 14;15(1):238-244. doi: 10.1159/000521840.
    • Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: A case report and review of the literature.
    • Nie X, Chen X, Jiang Y, Zhong Y, Chen T, Cheng W.
    • Medicine (Baltimore). 2022 Feb 11;101(6):e28712. doi: 10.1097/MD.0000000000028712.
    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.
    • Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
    • Philp L, Alimena S, Ferris W, Saini A, Bregar AJ, Del Carmen MG, Eisenhauer EL, Growdon WB, Goodman A, Dorney K, Mazina V, Sisodia RC.
    • Gynecol Oncol. 2022 Feb;164(2):421-427. doi: 10.1016/j.ygyno.2021.12.017. Epub 2021 Dec 23.
    • Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?
    • Ghirardi V, De Felice F, D'Indinosante M, Bernardini F, Giudice MT, Fagotti A, Scambia G.
    • Cancer Treat Res Commun. 2022;31:100518. doi: 10.1016/j.ctarc.2022.100518. Epub 2022 Jan 14.
    • Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
    • Azribi F, Abdou E, Dawoud E, Ashour M, Kamal A, Al Sayed M, Burney I.
    • BMC Cancer. 2021 Dec 20;21(1):1350. doi: 10.1186/s12885-021-09094-8.
    • Mise à jour 2021 des recommandations pour la pratique clinique de Nice/Saint-Paul-de-Vence dans le cancer de l’ovaire épithélial de haut grade: Updated 2021 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in epithelial high grade ovarian cancer.
    • Joly F, Ray-Coquard I.
    • Bull Cancer. 2021 Dec;108(9S1):S1-S4. French. doi: 10.1016/S0007-4551(21)00581-6.
    • Guideline, [Article in French]
    • Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    • Azzalini E, Barbazza R, Stanta G, Giorda G, Bortot L, Bartoletti M, Puglisi F, Canzonieri V, Bonin S.
    • Gynecol Oncol. 2021 Dec;163(3):498-505. doi: 10.1016/j.ygyno.2021.09.012. Epub 2021 Oct 1.
    • Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    • Ataseven B, Tripon D, Schwameis R, Harter P, Rhiem K, Schneider S, Heikaus S, Baert T, Francesco AP, Heitz F, Traut A, Groeben HT, Schmutzler R, du Bois A.
    • Gynecol Oncol. 2021 Dec;163(3):569-577. doi: 10.1016/j.ygyno.2021.09.004. Epub 2021 Sep 24.
    • Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
    • Klotz DM, Link T, Wimberger P, Kuhlmann JD.
    • Mol Oncol. 2021 Dec;15(12):3626-3638. doi: 10.1002/1878-0261.12949. Epub 2021 Apr 2.
    • The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.
    • You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson RT, Pignata S, Pujade-Lauraine E.
    • Cancer Treat Rev. 2021 Nov;100:102294. doi: 10.1016/j.ctrv.2021.102294. Epub 2021 Sep 15.
    • Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018.
    • Westin SN, Louie-Gao M, Gupta D, Thaker PH.
    • Future Oncol. 2021 Nov;17(32):4263-4274. doi: 10.2217/fon-2021-0018. Epub 2021 Aug 11.
    • Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    • Saccardi C, Zovato S, Spagnol G, Bonaldo G, Marchetti M, Alessandrini L, Tognazzo S, Guerriero A, Vitagliano A, Laganà AS, Noventa M.
    • Gynecol Oncol. 2021 Nov;163(2):364-370. doi: 10.1016/j.ygyno.2021.08.021. Epub 2021 Aug 28.
    • Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer.
    • Drouin L, Guani B, Balaya V, Azaïs H, Betrian S, Bolze PA, Dabi Y, Kerbage Y, Sanson C, Zaccarini F, Mathevet P, Lécuru F, Guyon F, Akladios C, Bendifallah S, Deluche E, On Behalf Of The Sfog Campus Young Of French Society Of Gynecological Oncology.
    • J Clin Med. 2021 Oct 21;10(21):4829. doi: 10.3390/jcm10214829.
    • Role of adjuvant and post-surgical treatment in gynaecological cancer.
    • Ngu SF, Ngan HY, Chan KK.
    • Best Pract Res Clin Obstet Gynaecol. 2021 Sep 15:S1521-6934(21)00124-3. doi: 10.1016/j.bpobgyn.2021.09.001. Epub ahead of print.
    • The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    • Kim SR, Malcolmson J, Li X, Bernardini MQ, Hogen L, May T.
    • Gynecol Oncol. 2021 Sep;162(3):702-706. doi: 10.1016/j.ygyno.2021.07.010. Epub 2021 Jul 10.
    • Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases.
    • Gallego A, Garrido D, Yébenes L, Mendiola M, Castelo B, Redondo A.
    • Int J Gynecol Cancer. 2021 Sep;31(9):1292-1296. doi: 10.1136/ijgc-2020-002225.
    • Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    • Manning-Geist BL, Chi DS, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr.
    • Gynecol Oncol. 2021 Aug;162(2):345-352. doi: 10.1016/j.ygyno.2021.05.015. Epub 2021 May 25.
    • Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial).
    • Marchetti C, Tudisco R, Salutari V, Pietragalla A, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2021 Jun 15:ijgc-2021-002727. doi: 10.1136/ijgc-2021-002727. Epub ahead of print.
    • NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer.
    • Marchetti C, D'Indinosante M, Bottoni C, Di Ilio C, Di Berardino S, Costantini B, Minucci A, Vertechy L, Scambia G, Fagotti A.
    • Sci Rep. 2021 May 27;11(1):11125. doi: 10.1038/s41598-021-90361-w.
    • Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
    • Cecere SC, Musacchio L, Bartoletti M, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Naglieri E, Scollo P, Marchetti C, Raspagliesi F, Greggi S, Cinieri S, Bergamini A, Orditura M, Valabrega G, Scambia G, Martinelli F, De Matteis E, Cardalesi C, Loizzi V, Perniola G, Carella C, Scandurra G, Giannone G, Pignata S.
    • Int J Gynecol Cancer. 2021 May 14:ijgc-2020-002343. doi: 10.1136/ijgc-2020-002343. Epub ahead of print.
    • A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report.
    • Blankenship L, Lyons YA, Dao Campi H, Valente PT, Barnes L, Kost ER.
    • Gynecol Oncol Rep. 2021 May 5;36:100772. doi: 10.1016/j.gore.2021.100772.
    • Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    • Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK.
    • Gynecol Oncol. 2021 Apr 7:S0090-8258(21)00272-9. doi: 10.1016/j.ygyno.2021.04.002. Epub ahead of print.
    • The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study.
    • Toss A, Piombino C, Tenedini E, Bologna A, Gasparini E, Tarantino V, Filieri ME, Cottafavi L, Giovanardi F, Madrigali S, Civallero M, Marcheselli L, Marchi I, Domati F, Venturelli M, Barbieri E, Grandi G, Tagliafico E, Cortesi L.
    • Diagnostics (Basel). 2021 Mar 21;11(3):565. doi: 10.3390/diagnostics11030565.
    • Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.
    • Conte C, Fagotti A, Avesani G, Trombadori C, Federico A, D'Indinosante M, Giudice MT, Pelligra S, Lodoli C, Marchetti C, Ferrandina G, Scambia G, Gallotta V.
    • Ann Transl Med. 2021 Mar;9(6):510. doi: 10.21037/atm-20-4690.
    • Suprarenal lymphadenectomy with nephrectomy for refractory ovarian cancer.
    • Park SJ, Kim HS.
    • Gland Surg. 2021 Mar;10(3):1268-1270. doi: 10.21037/gs.2020.04.08.
    • The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
    • Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, Satoh T, Hirashima Y, Matsumura N, Yokoyama Y, Kawana K, Kyo S, Aoki D, Katabuchi H.
    • J Gynecol Oncol. 2021 Mar;32(2):e49. doi: 10.3802/jgo.2021.32.e49.
    • Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review.
    • Schuurman T, Zilver S, Samuels S, Schats W, Amant F, van Trommel N, Lok C.
    • Cancers (Basel). 2021 Feb 28;13(5):E1008. doi: 10.3390/cancers13051008.
    • Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
    • How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS.
    • Cancers (Basel). 2021 Feb 24;13(5):946. doi: 10.3390/cancers13050946.
    • Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis.
    • Baum J, Braicu EI, Hunsicker O, Vergote I, Concin N, Van Nieuwenhuysen E, Feldheiser A, Achimas-Cadariu P, Darb-Esfahani S, Berger A, Fetica B, Mahner S, Papadia A, Wölber L, Gasparri ML, Vanderstichele A, Benedetti Panici P, Mueller MD, Ruscito I, Woopen H, Sehouli J.
    • Int J Gynecol Cancer. 2021 Feb 9:ijgc-2020-002023. doi: 10.1136/ijgc-2020-002023. Epub ahead of print.
    • BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography.
    • Sobecki JN, Dryer KA, Mahajan AM, Spencer RJ.
    • Gynecol Oncol Rep. 2020 Dec 25;35:100690. doi: 10.1016/j.gore.2020.100690. eCollection 2021 Feb.
    • Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
    • Kurnit KC, Fleming GF, Lengyel E.
    • Obstet Gynecol. 2021 Jan 1;137(1):108-121. doi: 10.1097/AOG.0000000000004173.
    • BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery.
    • Ponzone R.
    • Crit Rev Oncol Hematol. 2021 Jan;157:103128. doi: 10.1016/j.critrevonc.2020.103128. Epub 2020 Oct 19.
    • Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    • Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.
    • Jpn J Clin Oncol. 2020 Dec 30:hyaa239. doi: 10.1093/jjco/hyaa239. Epub ahead of print.
    • Treatment of Recurrent Epithelial Ovarian Cancer.
    • Claussen C, Rody A, Hanker L.
    • Geburtshilfe Frauenheilkd. 2020 Dec;80(12):1195-1204. doi: 10.1055/a-1128-0280. Epub 2020 Dec 3.
    • Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery.
    • Estati FL, Pirolli R, de Alencar VTL, Ribeiro ARG, Formiga MN, Torrezan GT, Carraro DM, Guimarães APG, Baiocchi G, da Costa AABA.
    • Ann Surg Oncol. 2020 Nov 21. doi: 10.1245/s10434-020-09366-w. Epub ahead of print.
    • Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    • Boerner T, Tanner E, Filippova O, Zhou QC, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Gardner GJ, Sonoda Y, Abu-Rustum NR, Zivanovic O, Long Roche K, Afonso AM, Fischer M, Chi DS.
    • Gynecol Oncol. 2020 Nov 16:S0090-8258(20)34064-6. doi: 10.1016/j.ygyno.2020.10.042. Epub ahead of print.
    • Advances in epithelial ovarian cancer.
    • Neesham D, Richards A, McGauran M.
    • Aust J Gen Pract. 2020 Oct;49(10):665-669.
    • Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
    • Weiss AS, Swisher E, Pennington KP, Radke M, Khasnavis N, Garcia RL, Kilgore MR, Lee MK, Norquist BM.
    • Gynecol Oncol. 2020 Oct;159(1):214-220. doi: 10.1016/j.ygyno.2020.06.509. Epub 2020 Jul 21.
    • Laparoscopic surgery for isolated inguinal node relapse of high grade serous ovarian cancer using a bipolar combination instrument.
    • Pecorino B, Scibilia G, Sozzi G, Giambanco L, Chiantera V, Scollo P.
    • Surg Oncol. 2020 Sep;34:283. doi: 10.1016/j.suronc.2020.04.008. Epub 2020 Apr 25.
    • Case report
    • Cytologic studies of in vivo fallopian tube specimens in patients undergoing salpingo-oophorectomy.
    • Pramanik S, Yang E, Wu W.
    • Cytojournal. 2020 Aug 10;17:19. doi: 10.25259/CytoJournal_7_2020.
    • Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    • DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN.
    • J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799. Epub ahead of print.
    • Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
    • Mitamura T, Sekine M, Arai M, Shibata Y, Kato M, Yokoyama S, Yamashita H, Watari H, Yabe I, Nomura H, Enomoto T, Nakamura S; Registration Committee of the Japanese HBOC Consortium.
    • Jpn J Clin Oncol. 2020 Jul 17:hyaa124. doi: 10.1093/jjco/hyaa124. Epub ahead of print.
    • Chemotherapy directly followed by PARP inhibition as an alternative to surgery in patients with BRCA- mutated ovarian cancer - a potential management strategy in the era of COVID-19.
    • Vetter MH, Smrz SA, Copeland LJ, Cohn DE.
    • Am J Obstet Gynecol. 2020 May 23:S0002-9378(20)30569-X. doi: 10.1016/j.ajog.2020.05.037. Epub ahead of print.
    • Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT).
    • Domchek SM, Brower J, Symecko H, Marcell V, Walsh MF, Hamilton JG, Couch F, Offit K, Garber JE, Robson ME.
    • J Clin Oncol. 2020 May 20;38(15 Suppl):1508-1508. doi: 10.1200/JCO.2020.38.15_suppl.1508. Epub 2020 May 25.
    • Conference abstract
    • A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
    • Shi T, Yin S, Zhu J, Zhang P, Liu J, Zhu Y, Wu S, Chen X, Wang X, Teng Y, Zhu T, Yu A, Zhang Y, Feng Y, Huang H, Bao W, Li Y, Jiang W, Zhang P, Li J, Ai Z, Zhang W, Jia H, Zhang Y, Jiang R, Zhang J, Gao W, Luan Y, Zang R.
    • J Gynecol Oncol. 2020 May;31(3):e61. doi: 10.3802/jgo.2020.31.e61.

    Related:

    Addendum:

    Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.

    Identifier: NCT03983226: Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial). (ClinicalTrials.gov)

    • Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.
    • Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    • BMC Cancer. 2020 Mar 4;20(1):185. doi: 10.1186/s12885-020-6688-8.
    • Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
    • Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno JC, Cardenas-Goicoechea J.
    • Obstet Gynecol Sci. 2020 Mar;63(2):205-208. doi: 10.5468/ogs.2020.63.2.205. Epub 2020 Feb 5.
    • Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC.
    • Iavazzo C, Fotiou A, Tsiatas M, Christopoulou A, Spiliotis J, Sugarbaker P.
    • Pleura Peritoneum. 2020 Feb 26;5(1):20190029. doi: 10.1515/pp-2019-0029.
    • Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
    • Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N.
    • Sci Rep. 2020 Feb 17;10(1):2757. doi: 10.1038/s41598-020-59671-3.
    • Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
    • Gallotta V, Bruno M, Conte C, Giudice MT, Davià F, Moro F, Zannoni GF, Fagotti A, De Bonis M, Capoluongo E, Scambia G, Ferrandina G.
    • Eur J Surg Oncol. 2020 Feb 6. pii: S0748-7983(20)30071-8. doi: 10.1016/j.ejso.2020.01.035. [Epub ahead of print]
    • Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    • Bixel K, Vetter M, Davidson B, Berchuck A, Cohn D, Copeland L, Fowler JM, Havrilesky L, Lee PS, O'Malley DM, Salani R, Valea F, Alvarez Secord A, Backes F.
    • Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837-2. doi: 10.1016/j.ygyno.2019.12.016. [Epub ahead of print]
    • Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors.
    • Zahari MM, Chiorean AR, Duma MM, Ungureanu A, Kacso G.
    • Arch Clin Cases. 2021 [2019?] Oct 27;6(3):69-75. doi: 10.22551/2019.24.0603.10156.
    • Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    • Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545-8. doi: 10.1016/j.ygyno.2019.09.020. [Epub ahead of print]
    • Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
    • Cybulska P, Hayes SA, Spirtos A, Rafizadeh MJ, Filippova OT, Leitao M, Zivanovic O, Sonoda Y, Mueller J, Lakhman Y, Long K, Chi DS.
    • Int J Gynecol Cancer. 2019 Oct 1. pii: ijgc-2019-000829. doi: 10.1136/ijgc-2019-000829. [Epub ahead of print]
    • Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?
    • Pietragalla A, Minucci A, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2019 Sep 19. pii: ijgc-2019-000757. doi: 10.1136/ijgc-2019-000757. [Epub ahead of print]
    • BRCA test: what is the correct timing for surgery?
    • Mirandola S, Invento A, Surci N, Pollini GP, Pellini F.
    • Eur J Cancer Prev. 2019 Sep;28(5):460-462. doi: 10.1097/CEJ.0000000000000509.
    • The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
    • Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, Achimas Cadariu P.
    • J BUON. 2019 Jul-Aug;24(4):1538-1543.
    • Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
    • Gallotta V, Conte C, D'Indinosante M, Capoluongo E, Minucci A, De Rose AM, Ardito F, Giuliante F, Di Giorgio A, Zannoni GF, Fagotti A, Margreiter C, Scambia G, Ferrandina G.
    • Eur J Surg Oncol. 2019 Jun 13. pii: S0748-7983(19)30517-7. doi: 10.1016/j.ejso.2019.06.023. [Epub ahead of print]
    • Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    • Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.
    • J Ovarian Res. 2019 May 7;12(1):40. doi: 10.1186/s13048-019-0511-7.
    • BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    • Gorodnova T, Sokolenko A, Ni V, Ivantsov A, Kotiv K, Petrik S, Amelina I, Berlev I, Imyanitov E.
    • Int J Gynecol Cancer. 2019 May;29(4):779-786. doi: 10.1136/ijgc-2018-000175. Epub 2019 Mar 5.
    • Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
    • Madariaga A, Lheureux S, Oza AM.
    • Cancers (Basel). 2019 Mar 23;11(3). pii: E416. doi: 10.3390/cancers11030416.
    • Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report.
    • Suda K, Nakaoka H, Hata C, Yahata N, Isobe M, Kameyama H, Wakai T, Motoyama T, Inoue I, Yoshihara K, Enomoto T.
    • Diagn Pathol. 2019 Feb 11;14(1):17. doi: 10.1186/s13000-019-0795-3.
    • Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    • Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.
    • J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
    • Principles of clinical management of ovarian cancer.
    • Gorodnova TV, Sokolenko AP, Kuligina E, Berlev IV, Imyanitov EN.
    • Chin Clin Oncol. 2018 Dec;7(6):56. doi: 10.21037/cco.2018.10.06.
    • Secondary cytoreduction in ovarian cancer: who really benefits?
    • Giudice MT, D'Indinosante M, Cappuccio S, Gallotta V, Fagotti A, Scambia G, Petrillo M.
    • Arch Gynecol Obstet. 2018 Nov;298(5):873-879. doi: 10.1007/s00404-018-4915-1. Epub 2018 Sep 25.
    • Review
    • Surgery in ovarian cancer - Brazilian Society of Surgical Oncology consensus.
    • Tsunoda AT, Ribeiro R, Reis RJ, da Cunha Andrade C, Moretti Marques R, Baiocchi G, Fin F, Zanvettor PH, Falcao D, Batista TP, Azevedo B, Guitmann G, Pessini SA, Nunes JS, Campbell LM, Linhares JC, Carneiro V, Coimbra F.
    • BJOG. 2018 Sep;125(10):1243-1252. doi: 10.1111/1471-0528.15328. Epub 2018 Jul 18.
    • Review
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.
    • Na K, Lee JY, Sung JY, Kim GM, Koo JS, Kim HS.
    • Virchows Arch. 2018 Aug;473(2):165-175. doi: 10.1007/s00428-018-2390-5. Epub 2018 Jun 20.
    • Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes.
    • Wong S, Ratner E, Buza N.
    • Histopathology. 2018 Jul;73(1):109-123. doi: 10.1111/his.13503. Epub 2018 Apr 16.
    • Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months.
    • Rizzo S, Botta F, Raimondi S, Origgi D, Buscarino V, Colarieti A, Tomao F, Aletti G, Zanagnolo V, Del Grande M, Colombo N, Bellomi M.
    • Eur Radiol. 2018 May 8. doi: 10.1007/s00330-018-5389-z. [Epub ahead of print]
    • Treatment of recurrent ovarian cancer.
    • Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F.
    • Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441.
    • Review, Conference abstract
    • Treatment of recurrent ovarian cancer.
    • Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F.
    • Ann Oncol. 2017 Nov;28 Suppl 8:viii51-viii56. doi: 10.1093/annonc/mdx441.
    • High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.
    • Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E.
    • Radiology. 2017 Nov;285(2):472-481. doi: 10.1148/radiol.2017161697. Epub 2017 Jun 16.
    • BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    • Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A.
    • Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23.
    • Malignant Brenner tumor associated with a germline BRCA2 mutation.
    • Toboni MD, Smith HJ, Dilley SE, Novak L, Leath CA.
    • Gynecol Oncol Rep. 2017 May 31;21:17-19. doi: 10.1016/j.gore.2017.05.006. eCollection 2017 Aug.
    • Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
    • Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, Del Carmen MG, Keating NL.
    • JAMA Oncol. 2017 Jan 1;3(1):76-82. doi: 10.1001/jamaoncol.2016.4411.
    • Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125.
    • Chudecka-Głaz A, Cymbaluk-Płoska A, Luterek-Puszyńska K, Menkiszak J.
    • Oncol Lett. 2016 Nov;12(5):3101-3114. Epub 2016 Aug 29.
    • Options in Prophylactic Surgery to Prevent Ovarian Cancer in High-Risk Women: How New Hypotheses of Fallopian Tube Origin Influence Recommendations.
    • Swanson CL, Bakkum-Gamez JN.
    • Curr Treat Options Oncol. 2016 May;17(5):20. doi: 10.1007/s11864-016-0396-2.
    • Review
    • Serous Tubal Intraepithelial Carcinoma Localizes to the Tubal-peritoneal Junction: A Pivotal Clue to the Site of Origin of Extrauterine High-grade Serous Carcinoma (Ovarian Cancer).
    • Seidman JD.
    • Int J Gynecol Pathol. 2015 Mar;34(2):112-20. doi: 10.1097/PGP.0000000000000123.
    • Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
    • Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM.
    • J Surg Oncol. 2014 Nov;110(6):661-5. doi: 10.1002/jso.23688. Epub 2014 Jun 24.
    • BRCA1/2 Mutation Status Is an Independent Factor of Improved Survival for Advanced (Stage III-IV) Ovarian Cancer.
    • Rudaitis V, Zvirblis T, Kanopiene D, Janulynaite D, Griskevicius L, Janavicius R.
    • Int J Gynecol Cancer. 2014 Oct;24(8):1395-400. doi: 10.1097/IGC.0000000000000247.
    • Clinical Outcome of Isolated Serous Tubal Intraepithelial Carcinomas (STIC).
    • Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, Otegbeye E, Sonoda Y, Abu-Rustum NR, Barakat RR, Levine DA, Gardner GJ.
    • Int J Gynecol Cancer. 2013 Nov;23(9):1603-11. doi: 10.1097/IGC.0b013e3182a80ac8.
    • Body Image and Sexuality After Surgery, Cancer and/or Treatment, for Survivors and Previvors.
    • Sharon Bober
    • FORCE. Be Empowered Webinars. 2013 Aug 28.
    • Intentions for bilateral mastectomy among newly diagnosed breast cancer patients.
    • King L, O'Neill SC, Spellman E, Peshkin BN, Valdimarsdottir H, Willey S, Leventhal KG, Demarco T, Nusbaum R, Feldman E, Jandorf L, Schwartz MD.
    • J Surg Oncol. 2013 Jun;107(7):772-6. doi: 10.1002/jso.23307. Epub 2012 Dec 27.
    • Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
    • Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Phillips MF, Spriggs DR, Soslow RA, Kauff ND, Levine DA.
    • Gynecol Oncol. 2012 Aug;126(2):224-8. doi: 10.1016/j.ygyno.2012.05.001. Epub 2012 May 8.